Sanofi is resisting the health crisis well

Sanofi is showing great resilience in this period of health crisis. After the jump in its net income in the second quarter (to 7.6 billion euros, against a loss of 87 million in the first quarter), the French pharmaceutical giant on Wednesday raised its earnings per share forecast for the entire 'year. This should grow by 6 to 7%, while so far the laboratory had expected an increase of 5%.

Read also: Sanofi wants to return to the forefront of research

Of course, Sanofi's quarterly results are mainly due to the sale at the end of May of almost all of its shares in the capital of the American biotech Regeneron, with which it notably developed its flagship drug, Dupixent, used among other things in the treatment. of atopic dermatitis. This operation should bring him in total more than ten billion euros.

But Sanofi was also able to count on the good performance of its activities. Its "net profit by activities" , which excludes certain exceptional items and serves as an internal benchmark

This article is for subscribers only. You have 67% left to discover.

Subscribe: 1 € for 2 months

Cancellable at any time

Already subscribed? Log in